A new lutein product, called Xantiol, has been created by the French company Nutralica and designed to help treat age-related macular degeneration (AMD).
Nutralica is a new company, created in March of this year after 18 months of research and development. One of the company's principal partners is the Brussels-based research organisation CERDEN, whose expertise in the field of nutritherapy - treating diseases with nutrients - was one of the driving forces behind Xantiol.
The lutein supplement - which also contains DHA, vitamin E, zinc and selenium - will be available in Germany and the Benelux countries, through the UNDA laboratory, from August of this year, with distribution to other European countries planned in due course.
A second supplement brand, Lipobiol, a treatment for diabetes and associated cardiovascular problems, will be launched later this year.
Both Xantiol and Lipobiol will be available only through scientific laboratories and national pharmaceutical distribution networks.